Petter Veiby
Chief Scientific OfficerDr. Petter Veiby, Ph.D., is Non-Executive Director at BiVictriX Therapeutics plc since September 2025. He is Chief Scientific Officer of Attovia Therapeutics, Inc since June 2023. Prior to joining Attovia, he was the Head of Alliances and BD Search and Evaluation at Zai Lab and built a team to manage 15 alliances and collaborations across discovery through commercialization. Before Zai Lab, he was in various leadership roles in the Oncology Drug Discovery Unit at Millennium/Takeda. From April 2022 to November 2022, he was Senior Vice President, Business Development at Immunitas Therapeutics, Inc. He has always had a passion for biotherapeutics. In his role as Global Head of Biotherapeutics at Takeda, he led the biotherapeutics strategy growing Takeda’s capabilities and pipeline of biologics through internal infrastructure build and numerous strategic partnerships leading to a deep pipeline of ADCs, bispecific immune cell engagers and cell therapies. While at Millennium, he led the biological validation of novel targets and oversaw numerous projects delivering IND-ready development candidates resulting in drugs like Ninlaro and Pevonedistat, with his efforts contributing to the acquisition of Millenium by Takeda. Dr. Veiby did his Ph.D. and postdoc studies in hematopoietic stem cell biology at University of Oslo in Norway and at Hipple Cancer Research Center/OSU. He has authored/co-authored >50 papers in peer reviewed journals.
Positions
- Company NameAttovia Therapeutics, Inc.Stock CodeATTOPositionChief Scientific OfficerColleagues
- TFTao FuCEO, President & Director
- JNJames Newman TopperIndependent Chairman of the Board
- HCHubert C. ChenChief Medical Officer
- SCSteven ChanChief Financial Officer
- HZHangjun ZhanChief Technology Officer
- MHMitchell H. GoldIndependent Director
- AJAngie J. YouIndependent Director
- JWJohn W. SmitherIndependent Director
